Payment overview · 2025
General Payments
$1,095.50
54 reported records · 13 companies
Healthcare provider profile · identity verified
Jerry Scott Harrison, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MADISON, MS · NPI 1003841073
Verified facts
What the public records show
CMS Open Payments records show Jerry Scott Harrison, M.D. received $1,095.50 in general payments during 2025 across 54 reported records.
Corcept Therapeutics accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $221.45 | 20.2% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $159.16 | 14.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.62 | 13.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.76 | 13.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $133.78 | 12.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.73 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.58 | 4.6% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.12 | 3.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.78 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.85 | 2.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $29.26 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.11 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.30 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,095.50 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $221.45 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.60 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.60 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $109.11 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $109.11 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.61 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $99.61 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.29 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.29 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $62.47 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $59.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.58 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 176 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
133 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
176 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 591 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 545 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 510 | 139 |
| Omeprazole | Omeprazole | 413 | 121 |
| Lisinopril | Lisinopril | 398 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 102 |
| Gabapentin | Gabapentin | 348 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 347 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 346 | 90 |
| Potassium Chloride | Potassium Chloride | 296 | 78 |
| Irbesartan | Irbesartan | 289 | 76 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 265 | 74 |
| Alprazolam | Alprazolam | 248 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 248 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 43 |
| Furosemide | Furosemide | 228 | 71 |
| Eliquis | Apixaban | 223 | 41 |
| Meloxicam | Meloxicam | 213 | 61 |
| Carvedilol | Carvedilol | 207 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 55 |
| Allopurinol | Allopurinol | 203 | 46 |
| Famotidine | Famotidine | 200 | 59 |
| Glimepiride | Glimepiride | 196 | 57 |
| Metformin Hcl | Metformin Hcl | 196 | 52 |
| Trazodone Hcl | Trazodone Hcl | 181 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 45 |
| Jardiance | Empagliflozin | 176 | 33 |
| Ezetimibe | Ezetimibe | 173 | 44 |
| Tramadol Hcl | Tramadol Hcl | 158 | 43 |
| Memantine Hcl | Memantine Hcl | 151 | 27 |
| Methylprednisolone | Methylprednisolone | 150 | 124 |
| Montelukast Sodium | Montelukast Sodium | 149 | 42 |
| Azithromycin | Azithromycin | 136 | 105 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 28 |
| Simvastatin | Simvastatin | 133 | 29 |
| Synthroid | Levothyroxine Sodium | 133 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 127 | 27 |
| Bupropion Xl | Bupropion Hcl | 122 | 27 |
| Losartan Potassium | Losartan Potassium | 122 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 17 |
| Donepezil Hcl | Donepezil Hcl | 114 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 49 |
| Sertraline Hcl | Sertraline Hcl | 108 | 25 |
| Xarelto | Rivaroxaban | 107 | 14 |
| Estradiol | Estradiol | 106 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 74 |
| Nifedipine Er | Nifedipine | 97 | 20 |
| Ozempic | Semaglutide | 93 | 16 |
| Azelastine Hcl | Azelastine Hcl | 89 | 46 |
| Prednisone | Prednisone | 87 | 48 |
| Fluconazole | Fluconazole | 86 | 38 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 86 | 22 |
| Farxiga | Dapagliflozin Propanediol | 85 | 15 |
| Spironolactone | Spironolactone | 82 | 23 |
| Mounjaro | Tirzepatide | 80 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 38 |
| Temazepam | Temazepam | 79 | 13 |
| Cefdinir | Cefdinir | 78 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 18 |
| Clonazepam | Clonazepam | 76 | 17 |
| Valsartan | Valsartan | 76 | 20 |
| Pregabalin | Pregabalin | 75 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 68 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 21 |
| Alendronate Sodium | Alendronate Sodium | 66 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 46 |
| Cefuroxime | Cefuroxime Axetil | 58 | 51 |
| Atenolol | Atenolol | 57 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 20 |
| Meclizine Hcl | Meclizine Hcl | 55 | 25 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 12 |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 18 |
| Colchicine | Colchicine | 45 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 13 |
| Baclofen | Baclofen | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Nabumetone | Nabumetone | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 16 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Baqsimi | Glucagon | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,095.50 · 54 records | Corcept Therapeutics | ABRYSVO, AREXVY, COMIRNATY, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, JARDIANCE, KISUNLA, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tresiba, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error